24 Restless Legs Syndrome
|
|
- Rosemary Annabel Haynes
- 7 years ago
- Views:
Transcription
1 24 Restless Legs Syndrome Mathew Clark, MD CONTENTS INTRODUCTION DESCRIPTION EPIDEMIOLOGY DIAGNOSIS TREATMENT MANAGEMENT OF RESTLESS LEGS SYNDROME SOURCES INTRODUCTION Restless legs syndrome (RLS) has been called the most common disorder that is never heard of. Although most primary care physicians have developed at least a passing familiarity with RLS in recent years, it remains true that this condition is very much underdiagnosed and undertreated. In an effort to promote more widespread awareness of RLS in the medical community and to share up-to-date knowledge regarding management of this condition, several guidelines, updates, and management algorithms have been published. These are summarized next. DESCRIPTION RLS has four essential diagnostic features: 1. An urge to move the legs, usually accompanied by uncomfortable sensations. 2. The urge to move or uncomfortable sensations that begin during periods of rest or inactivity. 3. These sensations are partially or totally but temporarily relieved by movement. 4. Symptoms are worse in the evening or at night. These symptoms may be infrequent, or they may be nearly constant, persisting throughout the day. Symptoms may be quite mild, and only noticeable in From: Current Clinical Practice: Essential Practice Guidelines in Primary Care Edited by: N. S. Skolnik Humana Press, Totowa, NJ 317
2 318 Clark certain situations, or they may be experienced as intense and nearly unbearable. Affected patients typically have trouble with sedentary activities, such as sitting through meetings, being a passenger on a long trip, or going to the theater. Insomnia is often a significant problem when the combination of inactivity and time of day may make initiation of sleep very difficult. Although RLS is by definition a condition that is experienced only during wakefulness, many patients with RLS also experience a related phenomenon, periodic leg movements of sleep (PLMS). PLMS condition causes stereotypical contractions of the legs as the patient sleeps. These contractions are often of sufficient intensity and frequency to significantly disrupt sleep. Accordingly, patients with RLS and PLMS often have trouble with both the initiation and maintenance of sleep, leading to significant daytime sleepiness and fatigue (1 3). EPIDEMIOLOGY In the United States, between 5 and 10% of the adult population experiences symptoms of RLS. Not all of these individuals will experience symptoms of sufficient frequency or intensity to warrant treatment. Symptoms tend to become more common with advancing age, and are more common in elderly patients than in young adults. There is a family history of RLS in two-thirds of affected patients. Most cases of RLS are idiopathic; the cause of these symptoms is currently not well understood. There are some conditions in which RLS is seen with greater frequency. Iron deficiency even at levels insufficient to cause anemia is associated with more frequent symptoms of RLS. Pregnancy is associated with RLS, with 19% of pregnant women reporting some symptoms; about one-third of these women describe their symptoms as severe. Patients with renal failure often experience RLS; studies have reported a prevalence of 20 57% in this population. DIAGNOSIS Diagnosis of RLS is by history. Patients should experience all four of the listed diagnostic criteria: the urge to move accompanied by dysesthesias, symptoms brought on at rest, relieved by movement, and worse in the evening or night. There is no role for a polysomnogram in diagnosing RLS, although this may be helpful in diagnosing PLMS. Iron status should be assessed. A serum ferritin is the recommended test; levels less than 50 are associated with a greater prevalence of RLS symptoms, even in the absence of anemia. TREATMENT Nonpharmacological Not all patients with RLS require treatment with medications. Recommended nonpharmacological measures include the following:
3 Chapter 24 / Restless Legs Syndrome 319 Replacement of iron, if iron deficiency is documented. Mental alerting activities, such as video games or crossword puzzles, at times of boredom/physical inactivity. Trial of abstinence from alcohol, nicotine, and caffeine. Trial of avoidance of medications with potential to worsen RLS symptoms. These medications include antidepressants (except buproprion), neuroleptic agents, dopamine-blocking antiemetics (such as metoclopramide), and sedating antihistamines. Medications The following classes of medications have demonstrated efficacy in treating RLS symptoms: Dopaminergic medications: Medications in this class include levodopa/carbidopa combinations (Sinemet) and the dopamine agonists (DA) such as pergolide (Permax), ropinirole (Requip), and pramipexole (Mirapex). Balancing their excellent track record in relieving RLS symptoms is a tendency to develop unacceptable side effects. These include augmentation (the development of RLS symptoms earlier in the day after a bedtime dose of medication) and rebound (a wearing off of medication with an increased intensity of symptoms). Approximately 70% of patients taking regular levodopa/carbidopa will develop augmentation or rebound. This statistic is considerably smaller for those using DA. Opioids: Even weak opioids such as codeine or propoxyphene may be helpful in RLS, as may the opioid agonist tramadol. Higher potency opioids such as hydrocodone, oxycodone, or methadone are often helpful in more severe cases when weaker opioids are ineffective. Concerns about side effects and dependence make this a second-line option in most algorithms, yet this class of medications has been shown to maintain efficacy over long periods without a need for dose escalation. Anticonvulsants: These includes both carbamazepine and gabapentin, which are effective in treating RLS. Use of these agents may be limited by concerns about cost and side effects. They may be particularly helpful in situations involving neuropathy or a painful quality to the RLS symptoms. Benzodiazepines: These agents have demonstrated efficacy in RLS, particularly in patients for whom sleep-onset insomnia is a primary concern. Use of these medications is limited by concerns about dependence, tolerance, and daytime drowsiness. Clonidine and magnesium: These medications have demonstrated efficacy in small trials. No specific recommendation is currently made regarding their use. MANAGEMENT OF RESTLESS LEGS SYNDROME For purposes of management, the algorithm of the Medical Advisory Board of the RLS Foundation divides RLS into intermittent, daily, and refractory types.
4 320 Clark Intermittent RLS Patients with intermittent RLS have symptoms that are troublesome enough, when present, to require treatment, but that do not occur frequently enough to necessitate daily treatment. Recommendations, in addition to nonpharmacological measures, include the intermittent use of the following medications: Carbidopa/levodopa, 25/100 (0.5 1 tablet) or controlled-release (CR) 25/100 (1 tablet) can be used at bedtime or for RLS associated with specific activities, such as airplane or lengthy car rides. DA. The nonergot DAs (ropinirole or pramipexole) appear to have fewer troublesome side effects. Because these medications take min to begin working, they are of limited usefulness once symptoms have begun. Low-potency opioids or opioid agonists, such as propoxyphene ( mg), codeine (30 60 mg), or tramadol ( mg). Benzodiazepines or benzodiazepine agonists (temazepam, triazolam, zolpidem, and zaleplon). Daily RLS Patients in this category have RLS that is frequent and troublesome enough to require daily therapy. Recommendations, in addition to nonpharmacological measures, include use of the following medications: DA are the drugs of choice in most patients with daily RLS. Pramipexole (Mirapex) is normally given as mg once daily, taken 2 h before major RLS symptoms usually start. This dose may be increased by mg for every 2 3 d until symptoms are relieved. Most patients need 0.5 mg or less; doses up to 2 mg may be needed. Ropinirole (Requip) is dosed at 0.25 mg daily, also 2 h before symptoms, and increased by 0.25 mg for every 2 3 d as needed. Most patients require 2 mg or less; doses up to 4 mg may be needed. Gabapentin may be an alternative choice, particularly when symptoms are painful as described earlier. The treatment is usually once or twice daily, given late in the afternoon or before sleep. Dosing may start at mg per dose; mean daily doses of mg were used in one trial. Low-potency opioids (e.g., codeine or propoxyphene) or tramadol may be an alternative choice. Refractory RLS Patients with refractory RLS symptoms have daily RLS treated with a DA with one or more of the following: inadequate initial response despite adequate doses, response that has become inadequate with time, intolerable adverse effects, augmentation that is not controllable with additional earlier doses of the drug. In addition to the following approaches, referral to a RLS specialist should be considered:
5 Chapter 24 / Restless Legs Syndrome 321 Change to gabapentin. Change to a different DA. Add gabapentin, a benzodiazepine, or an opioid. Change to a high-potency opioid (oxycodone 5 15 mg), hydrocodone (5 15 mg), methadone (5 10 mg), or tramadol ( mg). No specific recommendations address the treatment of RLS in pregnant women or children. SOURCES 1. Hening W, Allen R, Earley C, Kushida C, Picchietti D, Silber M (1999) The treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine Review. Sleep 22: Hening WA, Allen RP, Earley CJ, Picchietti DL, Silber MH (2004) Restless Legs Syndrome Task Force of the Standards of Practice Committee of the American Academy of Sleep Medicine. An update on the dopaminergic treatment of restless legs syndrome and periodic limb movement disorder. Sleep 27: Silber MH, Ehrenberg BL, Allen RP, et al. (2004) Medical Advisory Boards of the Restless Legs Syndrome Foundation. An algorithm for the management of restless legs syndrome. Mayo Clin Proc 79(7):
SUMMARY OF RECOMMENDATIONS
SUMMARY OF RECOMMENDATIONS FOR THE LONG- TERM TREATMENT OF RLS/WED from AN IRLSSG TASK FORCE Members of the Task Force Diego Garcia- Borreguero, MD, Madrid, Spain* Richard Allen, PhD, Baltimore, MD, USA*
More informationRESTLESS LEGS SYNDROME FOUNDATION
RESTLESS LEGS SYNDROME Causes, diagnosis and treatment for the patient living with Restless Legs Syndrome (RLS) RESTLESS LEGS SYNDROME FOUNDATION DO I HAVE RESTLESS LEGS SYNDROME? Chances are, if you are
More informationRestless Legs Syndrome
CLINICAL REVIEW Restless Legs Syndrome Mathew M. Clark, MD Background: Restless legs syndrome is a common but not well-recognized central nervous system disorder that leads to insomnia and daytime distress.
More information1/25/2015. Idiopathic restless legs syndrome: clinical definition, pathophysiology and treatment. Five essential criteria (all must be met)
Idiopathic restless legs syndrome: clinical definition, pathophysiology and treatment Joan Santamaria, MD Neurology service, Multidisciplinary Sleep Disorders Unit Hospital Clínic de Barcelona University
More informationSleep Difficulties. Insomnia. By Thomas Freedom, MD and Johan Samanta, MD
Sleep Difficulties By Thomas Freedom, MD and Johan Samanta, MD For most people, night is a time of rest and renewal; however, for many people with Parkinson s disease nighttime is a struggle to get the
More informationSLEEP DIFFICULTIES AND PARKINSON S DISEASE Julie H. Carter, R.N., M.S., A.N.P.
SLEEP DIFFICULTIES AND PARKINSON S DISEASE Julie H. Carter, R.N., M.S., A.N.P. Problems with sleep are common in Parkinson s disease. They can sometimes interfere with quality of life. It is helpful to
More informationRestless Legs Syndrome
Max Bayard, MD; Thomas Avonda, MD; and James Wadzinski, MD, East Tennessee State University, Quillen College of Medicine, Johnson City, Tennessee Restless legs syndrome is a common neurologic movement
More informationRestless Legs Syndrome: Who are Willis and Ekbom?
Restless Legs Syndrome: Who are Willis and Ekbom? Rochelle Goldberg, MD, FAASM, FCCP Associate Professor, Sidney Kimmel Medical Center, Thomas Jefferson University Director, Sleep Medicine Services Main
More informationSLEEP AND PARKINSON S DISEASE
A Practical Guide on SLEEP AND PARKINSON S DISEASE MICHAELJFOX.ORG Introduction Many people with Parkinson s disease (PD) have trouble falling asleep or staying asleep at night. Some sleep problems are
More informationNursing Interventions for Sleep Disorders Following TBI
Nursing Interventions for Sleep Disorders Following TBI Kadesha Clark, RN BSN When you sleep, your body rests and restores its energy levels. A good night's sleep is often the best way to help you cope
More informationSLEEP DISTURBANCE AND PSYCHIATRIC DISORDERS
E-Resource December, 2013 SLEEP DISTURBANCE AND PSYCHIATRIC DISORDERS Between 10-18% of adults in the general population and up to 50% of adults in the primary care setting have difficulty sleeping. Sleep
More informationUpdate on Buprenorphine: Induction and Ongoing Care
Update on Buprenorphine: Induction and Ongoing Care Elizabeth F. Howell, M.D., DFAPA, FASAM Department of Psychiatry, University of Utah School of Medicine North Carolina Addiction Medicine Conference
More informationCurrent Treatments for Restless Leg Syndrome
Current Treatments for Restless Leg Syndrome Release Date: 02/15/2012 Expiration Date: 02/15/2015 FACULTY: Lenore Howe, BS, MS FACULTY AND ACCREDITOR DISCLOSURE STATEMENTS: Ms. Howe has no actual or potential
More informationSleep Disorders in Geriatrics. Beth A. Malow, M.D., M.S. Associate Professor of Neurology Director, Vanderbilt Sleep Disorders Center
Sleep Disorders in Geriatrics Beth A. Malow, M.D., M.S. Associate Professor of Neurology Director, Vanderbilt Sleep Disorders Center Presentation Goals To recognize the prevalence and impact of treating
More informationGUIDELINES FOR USE OF PSYCHOTHERAPEUTIC MEDICATIONS IN OLDER ADULTS
GUIDELINES GUIDELINES FOR USE OF PSYCHOTHERAPEUTIC MEDICATIONS IN OLDER ADULTS Preamble The American Society of Consultant Pharmacists has developed these guidelines for use of psychotherapeutic medications
More informationMANAGEMENT OF CHRONIC NON MALIGNANT PAIN
MANAGEMENT OF CHRONIC NON MALIGNANT PAIN Introduction The Manitoba Prescribing Practices Program (MPPP) recognizes the important role served by physicians in relieving pain and suffering and acknowledges
More informationMOH CLINICAL PRACTICE GUIDELINES 2/2008 Prescribing of Benzodiazepines
MOH CLINICL PRCTICE GUIELINES 2/2008 Prescribing of Benzodiazepines College of Family Physicians, Singapore cademy of Medicine, Singapore Executive summary of recommendations etails of recommendations
More informationA Healthy Life RETT SYNDROME AND SLEEP. Exercise. Sleep. Diet 1. WHY SLEEP? 4. ARE SLEEP PROBLEMS A COMMON PARENT COMPLAINT?
Diet Sleep Exercise RETT SYNDROME AND SLEEP DR. DANIEL GLAZE, MEDICAL DIRECTOR THE BLUE BIRD CIRCLE RETT CENTER A good night s sleep promotes learning, improved mood, general good health, and a better
More informationSome people with Parkinson s experience restless legs syndrome.
Symptoms and lifestyle Restless legs syndrome and Parkinson s Some people with Parkinson s experience restless legs syndrome. This information sheet explains what restless legs syndrome is, what the symptoms
More informationComorbid Conditions in Autism Spectrum Illness. David Ermer MD June 13, 2014
Comorbid Conditions in Autism Spectrum Illness David Ermer MD June 13, 2014 Overview Diagnosing comorbidities in autism spectrum illnesses Treatment issues specific to autism spectrum illnesses Treatment
More informationClinical Algorithm & Preferred Medications to Treat Pain in Dialysis Patients
Clinical Algorithm & Preferred Medications to Treat Pain in Dialysis Patients Developed by the Mid Atlantic Renal Coalition and the Kidney End of Life Coalition September 2009 This project was supported,
More informationMEDICATION ABUSE IN OLDER ADULTS
MEDICATION ABUSE IN OLDER ADULTS Clifford Milo Singer, MD Adjunct Professor, University of Maine, Orono ME Chief, Division of Geriatric Mental Health and Neuropsychiatry The Acadia Hospital and Eastern
More informationOpioid Prescribing for Chronic Pain: Guidelines for Marin County Clinicians
Opioid Prescribing for Chronic Pain: Guidelines for Marin County Clinicians Although prescription pain medications are intended to improve the lives of people with pain, their increased use and misuse
More informationManaging Chronic Pain in Adults with Substance Use Disorders
Question from chapter 1 Managing Chronic Pain in Adults with Substance Use Disorders 1) What is the percent of chronic pain patients who may have addictive disorders? a) 12% b) 22% c) 32% d) 42% 2) Which
More informationAlgorithm for Initiating Antidepressant Therapy in Depression
Algorithm for Initiating Antidepressant Therapy in Depression Refer for psychotherapy if patient preference or add cognitive behavioural office skills to antidepressant medication Moderate to Severe depression
More informationNUVIGIL (armodafinil) oral tablet
NUVIGIL (armodafinil) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationBenzodiazepine & Z drugs withdrawal protocol
Benzodiazepine & Z drugs withdrawal protocol Rationale The NSF for Older People has highlighted the issues of dependence, sedation and fall in the elderly when taking these types of medications. It has
More informationSLEEP QUESTIONNAIRE THE EPWORTH SLEEPINESS SCALE
SLEEP QUESTIONNAIRE Patient Name: Height: Weight: Date : My Main Sleep Complaint(s) : Trouble sleeping at night.. yes no Falling asleep.. yes no Staying asleep.. yes no Snoring. yes no Stop breathing yes
More informationThe CCB Science 2 Service Distance Learning Program
S2S 2055 DETOXIFICATION Module 1 Post-Test 1. A common use of a biochemical marker is. a. to support or refute other information that leads to proper diagnosis b. for forensic purposes c. in detecting
More informationAssessment and Management of Opioid, Benzodiazepine, and Sedative-Hypnotic Withdrawal
Assessment and Management of Opioid, Benzodiazepine, and Sedative-Hypnotic Withdrawal Roger Cicala, M. D. Assistant Medical Director Tennessee Physician s Wellness Program Step 1 Don t 1 It is legal in
More informationUnderstanding Your Pain
Toll Free: 800-462-3636 Web: www.endo.com Understanding Your Pain This brochure was developed by Margo McCaffery, RN, MS, FAAN, and Chris Pasero, RN, MS, FAAN authors of Pain: Clinical Manual (2nd ed.
More informationPrescribing and Tapering Benzodiazepines
E-Resource October, 2014 Prescribing and Tapering Benzodiazepines The use of benzodiazepines has grown over time and evidence has shown that long term use of these drugs has very little benefit with many
More informationUniversity at Buffalo School of Pharmacy and Pharmaceutical Sciences Drug Information Response Documentation. Module Dates:
University at Buffalo School of Pharmacy and Pharmaceutical Sciences Drug Information Response Documentation Module Dates: 10/24/05-11/30/05 Preceptor Name: Dr. Tammie Lee Demler Name of Clerkship: Applied
More informationReview of Pharmacological Pain Management
Review of Pharmacological Pain Management CHAMP Activities are possible with generous support from The Atlantic Philanthropies and The John A. Hartford Foundation The WHO Pain Ladder The World Health Organization
More informationBenzodiazepines: A Model for Central Nervous System (CNS) Depressants
Benzodiazepines: A Model for Central Nervous System (CNS) Depressants Objectives Summarize the basic mechanism by which benzodiazepines work in the brain. Describe two strategies for reducing and/or eliminating
More informationOpiates Heroin/Prescription Steve Hanson Opiates Dates to 4,000 BC Mimics endorphin activity Natural - Opium, morphine, codeine Semi-synthetic- Heroin, Dilaudid Synthetics - Darvon, Demerol, Fentanyl Modern
More informationRestless Legs Syndrome Creepy-Crawly Legs Causing Distress?
written by Harvard Medical School Restless Legs Syndrome Creepy-Crawly Legs Causing Distress? www.patientedu.org Although many of us take it for granted, sleep is very important for health. For some 12
More informationElements for a public summary. VI.2.1 Overview of disease epidemiology. VI.2.2 Summary of treatment benefits
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Pain is one of the most common reasons for a patient to seek medical attention. Moderate or severe intensity pain can be acute
More informationCENTRAL NERVOUS SYSTEM MANAGEMENT OF PARKINSON S DISEASE
MANAGEMENT CENTRAL NERVOUS SYSTEM MANAGEMENT OF PARKINSON S DISEASE Parkinson s Disease is classically determined by the triad or rest tremor (usually starting in one arm) with bradykinesia (slowing of
More informationThe ABCs of Medication Assisted Treatment
The ABCs of Medication Assisted Treatment J E F F R E Y Q U A M M E, E X E C U T I V E D I R E C T O R C O N N E C T I C U T C E R T I F I C A T I O N B O A R D The ABCs of Medication Assisted Treatment
More informationCONCORD INTERNAL MEDICINE TESTOSTERONE DEFICIENCY PROTOCOL
CONCORD INTERNAL MEDICINE TESTOSTERONE DEFICIENCY PROTOCOL Douglas G. Kelling, Jr., MD Carmella Gismondi-Eagan, MD, FACP George C. Monroe, III, MD Revised April 29, 2012 The information contained in this
More informationDon t just dream of higher-quality sleep. How health care should be
Don t just dream of higher-quality sleep. How health care should be Many of our patients with sleep disorders don t realize there s another way of life, a better way, until they are treated. Robert Israel,
More informationChanges in the Evaluation and Treatment of Sleep Apnea
Changes in the Evaluation and Treatment of Sleep Apnea Joseph DellaValla, MD FACP Medical Director Center for Sleep Medicine At Androscoggin Valley Hospital Sleep Related Breathing Problems Obstructive
More informationOpioid/Opiate Dependent Pregnant Women
Opioid/Opiate Dependent Pregnant Women The epidemic, safety, stigma, and how to help. Presented by Lisa Ramirez MA,LCDC & Kerby Stewart MD The prescription painkiller epidemic is killing more women than
More informationAbstral Prescriber and Pharmacist Guide
Abstral Prescriber and Pharmacist Guide fentanyl citrate sublingual tablets Introduction The Abstral Prescriber and Pharmacist Guide is designed to support healthcare professionals in the diagnosis of
More informationAppendix to Tennessee Department of Health: Tennessee Clinical Practice Guidelines for Outpatient Management of Chronic Non- Malignant Pain
Appendix to Tennessee Department of Health: Tennessee Clinical Practice Guidelines for Outpatient Management of Chronic Non- Malignant Pain Division of Workers Compensation 04.01.2015 Background Opioids
More informationDosing Guide. For Optimal Management of Opioid Dependence
Dosing Guide For Optimal Management of Opioid Dependence KEY POINTS The goal of induction is to safely suppress opioid withdrawal as rapidly as possible with adequate doses of Suboxone (buprenorphine HCl/naloxone
More informationMedical marijuana for pain and anxiety: A primer for methadone physicians. Meldon Kahan MD CPSO Methadone Prescribers Conference November 6, 2015
Medical marijuana for pain and anxiety: A primer for methadone physicians Meldon Kahan MD CPSO Methadone Prescribers Conference November 6, 2015 Conflict of interest statement No conflict of interest to
More informationDavid W. Brandes, MS, MD, FAAN Hope MS Center, Knoxville, TN Director, Rest Analysis, Los Angeles, CA Asst. Clinical Professor, UCLA
David W. Brandes, MS, MD, FAAN Hope MS Center, Knoxville, TN Director, Rest Analysis, Los Angeles, CA Asst. Clinical Professor, UCLA Mrs. Smith: Doctor, I m tired all the time. Doctor: What do you mean
More informationFraud, Waste and Abuse
Fraud, Waste and Abuse CT - Fraud Hotline submitted by Connecticut The Fraud Hotline at the Department of Social Services (DSS) is a proactive approach to handling complaints regarding fraud and abuse
More informationWhat You Need to Know About Xenazine
Note to Healthcare Professionals: Please provide this guide to your patient or your patient s caregiver. What You Need to Know About Xenazine (tetrabenazine) Patient/Caregiver Counseling Guide This guide
More informationInformation for Pharmacists
Page 43 by 42 CFR part 2. A general authorization for the release of medical or other information is NOT sufficient for this purpose. Information for Pharmacists SUBOXONE (buprenorphine HCl/naloxone HCl
More informationMedical Information to Support the Decisions of TUECs INTRINSIC SLEEP DISORDERS
Introduction Excessive daytime sleepiness (EDS) is a common complaint. Causes of EDS are numerous and include: o Intrinsic sleep disorders (e.g. narcolepsy, obstructive sleep apnoea/hypopnea syndrome (OSAHS)
More informationPrimary Care Management of Sleep Complaints in Adults
Scope Primary Care Management of Sleep Complaints in Adults (Revised 2004) This guideline is for the primary care management of non-respiratory sleep disorders in adults and follows the DSM-IV-TR classification
More informationDisordered sleep at night has long been
Neurology 59 Excessive daytime sleepiness in PD Excessive Daytime Sleepiness (EDS) in Parkinson s disease (PD) is an important issue that warrants serious attention because it can have adverse effects
More informationRestless Legs Syndrome: Update on Diagnosis, Treatment, and Exciting Research
Restless Legs Syndrome: Update on Diagnosis, Treatment, and Exciting Research Charles H. Adler, M.D., Ph.D. Professor of Neurology Mayo Clinic College of Medicine Senior Clinical Scientist Banner Sun Health
More informationConsiderations when Using Controlled Substances to Treat Chronic Pain
Considerations when Using Controlled Substances to Treat Chronic Pain By Mary-Beth F. Plum, Pharm.D. Impact of Chronic Pain Acute pain is the body s response to environmental dangers, and it helps protect
More informationHEADACHES IN CHILDREN AND ADOLESCENTS. Brian D. Ryals, M.D.
HEADACHES IN CHILDREN AND ADOLESCENTS Brian D. Ryals, M.D. Frequency and Type of Headaches in Schoolchildren 8993 children age 7-15 in Sweden Migraine in 4% Frequent Nonmigrainous in 7% Infrequent Nonmigrainous
More informationDoncaster & Bassetlaw Medicines Formulary
Doncaster & Bassetlaw Medicines Formulary Section 4.9: Drugs Used in Parkinsonism and related Disorders Co-Beneldopa 12.5/50, 25/100 and 50/200 (Madopar) Capsules Co-Beneldopa 12.5/50 and 25/100 Dispersible
More informationDEPRESSION CARE PROCESS STEP EXPECTATIONS RATIONALE
1 DEPRESSION CARE PROCESS STEP EXPECTATIONS RATIONALE ASSESSMENT/PROBLEM RECOGNITION 1. Did the staff and physician seek and document risk factors for depression and any history of depression? 2. Did staff
More informationMEDICATION GUIDE WELLBUTRIN (WELL byu-trin) (bupropion hydrochloride) Tablets
MEDICATION GUIDE WELLBUTRIN (WELL byu-trin) (bupropion hydrochloride) Tablets Read this Medication Guide carefully before you start using WELLBUTRIN and each time you get a refill. There may be new information.
More informationBuprenorphine/Naloxone Maintenance Treatment for Opioid Dependence
Buprenorphine/Naloxone Maintenance Treatment for Opioid Dependence Information for Family Members Family members of patients who have been prescribed buprenorphine/naloxone for treatment of opioid addiction
More informationPrescription Drugs: Abuse and Addiction
EAP Drug Free Workplace Newsletter March 2014 Prescription Drugs: Abuse and Addiction What are some of the commonly abused prescription drugs? Although many prescription drugs can be abused or misused,
More informationOPIOIDS. Petros Levounis, MD, MA Chair Department of Psychiatry Rutgers New Jersey Medical School
OPIOIDS Petros Levounis, MD, MA Chair Department of Psychiatry Rutgers New Jersey Medical School Rutgers New Jersey Medical School Fundamentals of Addiction Medicine Summer Series Newark, NJ July 24, 2013
More informationAdjunctive psychosocial intervention. Conditions requiring dose reduction. Immediate, peak plasma concentration is reached within 1 hour.
Shared Care Guideline for Prescription and monitoring of Naltrexone Hydrochloride in alcohol dependence Author(s)/Originator(s): (please state author name and department) Dr Daly - Consultant Psychiatrist,
More informationPain Medication Taper Regimen Time frame to taper off 30-60 days
Pain Medication Taper Regimen Time frame to taper off 30-60 days Medication to taper Taper Regimen Comments Methadone Taper by no more than 25% Morphine Taper by no more than 25% Tramadol Taper by no more
More informationDEPRESSION Depression Assessment PHQ-9 Screening tool Depression treatment Treatment flow chart Medications Patient Resource
E-Resource March, 2015 DEPRESSION Depression Assessment PHQ-9 Screening tool Depression treatment Treatment flow chart Medications Patient Resource Depression affects approximately 20% of the general population
More informationTreatment of Anxiety in the Methadone Maintained Patient
Treatment of Anxiety in the Methadone Maintained Patient Abigail Kay M.D., M.A. Medical Director Narcotic Addiction Rehabilitation Program Department of Psychiatry and Human Behavior Thomas Jefferson University
More informationCOUNTY OF LOS ANGELES - DEPARTMENT OF MENTAL HEALTH OFFICE OF THE MEDICAL DIRECTOR. 3.4 PARAMETERS FOR THE USE OF ANXIOLYTIC MEDICATIONS October 2014
COUNTY OF LOS ANGELES - DEPARTMENT OF MENTAL HEALTH OFFICE OF THE MEDICAL DIRECTOR 3.4 PARAMETERS FOR THE USE OF ANXIOLYTIC MEDICATIONS October 2014 I. GENERAL CONSIDERATIONS A. Definition: Anxiolytic
More informationPain Management in Palliative and Hospice Care
Pain Management in Palliative and Hospice Care Donna Butler, MSN, ANP-BC, OCN, ACHPN, FAAPM Current Status of Pain Cancer patients at EOL- 54% have pain AIDS with prognosis < 6mons- intense pain Less research
More informationPolicy for the issue of permits to prescribe Schedule 8 poisons
Policy for the issue of permits to prescribe Schedule 8 poisons May 2011 Introduction The Victorian Drugs, Poisons and Controlled Substances (DPCS) legislation sets out certain circumstances when a medical
More informationTreatment of opioid use disorders
Treatment of opioid use disorders Gerardo Gonzalez, MD Associate Professor of Psychiatry Director, Division of Addiction Psychiatry Disclosures I have no financial conflicts to disclose I will review evidence
More informationWhy are you being seen at Frontier Diagnostic Sleep Center?
8425 South 84th Street Suite B Omaha, NE 68127 Phone: 402.339.7378 Fax: 402.339.9455 SLEEP QUESTIONNAIRE NAME: ADDRESS: Last First MI Street Address DATE City State Zip PHONE: ( ) BIRTHDATE: HEIGHT: WEIGHT:
More informationAmitriptyline. Drug information Amitriptyline
Drug information Amitriptyline Amitriptyline This leaflet provides information on amitriptyline and will answer any questions you have about the treatment. Arthritis Research UK produce and print our booklets
More informationClinic Reference Guide
Clinic Reference Guide 2010 Alliance Toxicology LLC PO Box 5000, PMB 190 Rancho Santa Fe, CA 92067 AllianceToxicologyLLCprovidesclinicaldrugtestingservicesforphysicians.Our companyprovidesacomprehensivedrugtestingpanelwhichincludesover40
More informationMedical Malpractice Treatment Alprazolam benzodiazepine - A Case Study
Improving Outcomes in Patients Who are Prescribed Alprazolam with Concurrent Use of Opioids Pik-Sai Yung, M.D. Staff Psychiatrist Center for Counseling at Walton Background and Rationale Alprazolam is
More informationMEDICATIONS AND PARKINSON'S DISEASE Cathi A.Thomas R.N., M.S.
MEDICATIONS AND PARKINSON'S DISEASE Cathi A.Thomas R.N., M.S. Medications to relieve or decrease symptoms of Parkinson s disease are an important and necessary part of care. For some people this may be
More informationPHARMACIST DETACH HERE AND GIVE TO PATIENT
PHARMACIST DETACH HERE AND GIVE TO PATIENT MEDICATION GUIDE HORIZANT (ho-ri' zant) (gabapentin enacarbil) Extended-Release Tablets Read this Medication Guide before you start taking HORIZANT and each time
More informationCare Manager Resources: Common Questions & Answers about Treatments for Depression
Care Manager Resources: Common Questions & Answers about Treatments for Depression Questions about Medications 1. How do antidepressants work? Antidepressants help restore the correct balance of certain
More informationBuilding a. With Your Doctor
Building a With Your Doctor As a mental health consumer, there are many things you can do to improve your care and get more out of life. Learning more about your illness, current treatment options and
More informationCorporate Medical Policy
Corporate Medical Policy Polysomnography for Non Respiratory Sleep Disorders File Name: Origination: Last CAP Review: Next CAP Review: Last Review: polysomnography_for_non_respiratory_sleep_disorders 10/2015
More informationParkinson's s disease - a
Parkinson's Disease Parkinson's s disease - a progressive disorder of the nervous system that affects movement. The most common perception of Parkinson s is the patient having tremors. Hands shaking, inability
More informationSativex. Spirella Building, Letchworth, SG6 4ET 01462 476700 www.mstrust.org.uk reg charity no. 1088353
Sativex Spirella Building, Letchworth, SG6 4ET 01462 476700 www.mstrust.org.uk reg charity no. 1088353 Sativex Date of issue: July 2010 Review date: July 2011 Contents 1. Introduction 1 2. What is Sativex?
More informationALCOHOL AND OTHER DRUG WITHDRAWAL: PRACTICE GUIDELINES
ALCOHOL AND OTHER DRUG WITHDRAWAL: PRACTICE GUIDELINES 2009 Pauline Kenny Amy Swan Lynda Berends Linda Jenner Barbara Hunter Janette Mugavin CHAPTER 14: CANNABIS WITHDRAWAL 14 CANNABIS These Guidelines
More informationDrug-Free Strategy in Treatment of Opiate Addiction in Russia
National Research Center on Addictions Russian Federation Ministry of Health Drug-Free Strategy in Treatment of Opiate Addiction in Russia Stanislav Mokhnachev,, M.D., Ph.D. Head of Drug Addiction Clinical
More informationNALTREXONE INDUCED DETOXIFICATION FROM OPIOIDS A METHOD OF ANTAGONIST INITIATED TREATMENT
NALTREXONE INDUCED DETOXIFICATION FROM OPIOIDS A METHOD OF ANTAGONIST INITIATED TREATMENT Opioid dependence is a devastating and frequently fatal medical condition. It is a manifestation of addictive disorder
More information03/20/12. Recognize the right of patients to appropriate assessment and management of pain
Narcotic Bowel Syndrome Alvin Zfass M.D. M.D. Professor of Medicine Toufic Kachaamy M.D. GI Fellow Chronic Pain 110 million Americans suffer from chronic pain according to the NIH Cost of untreated t or
More informationPATIENT INFORMATION SHEET CHRONIC MIGRAINE
1 PATIENT INFORMATION SHEET CHRONIC MIGRAINE Dr Nicholas Silver, Consultant Neurologist, the Walton Centre NHS Foundation Trust Chronic Migraine Chronic Migraine is a condition that may cause many different
More informationInformation About Benzodiazepines
Information About Benzodiazepines What are benzodiazepines? Benzodiazepines are psycho tropic drugs - drugs that affect the mind and are mood altering. They are commonly known as minor tranquillisers and
More informationDEMENTIA EDUCATION & TRAINING PROGRAM
The pharmacological management of aggression in the nursing home requires careful assessment and methodical treatment to assure maximum safety for patients, nursing home residents and staff. Aggressive
More informationMEDICATION GUIDE. Bupropion Hydrochloride (bue-proe-pee-on HYE-droe-KLOR-ide) Extended-Release Tablets, USP (SR)
MEDICATION GUIDE Bupropion Hydrochloride (bue-proe-pee-on HYE-droe-KLOR-ide) Extended-Release Tablets, USP (SR) Read this Medication Guide carefully before you start taking bupropion hydrochloride extendedrelease
More informationElizabeth A. Crocco, MD Assistant Clinical Professor Chief, Division of Geriatric Psychiatry Department of Psychiatry and Behavioral Sciences Miller
Elizabeth A. Crocco, MD Assistant Clinical Professor Chief, Division of Geriatric Psychiatry Department of Psychiatry and Behavioral Sciences Miller School of Medicine/University of Miami Question 1 You
More informationDisclosure Statement. Nursing Facility Regulations and Psychotropic Medication Use. Learning Objectives (Cont) Learning Objectives
Nursing Facility Regulations and Psychotropic Medication Use Jeffrey C. Reist PharmD, BCPS College of Pharmacy The University of Iowa December 2010 Disclosure Statement I, Jeffrey Reist, PharmD, BCPS do
More informationANCILLARY STABILIZATION AND WITHDRAWAL. The Why And How Of Stabilizing The Patient In A Comprehensive Treatment Setting
ANCILLARY STABILIZATION AND WITHDRAWAL The Why And How Of Stabilizing The Patient In A Comprehensive Treatment Setting About CASAColumbia A science-based, multidisciplinary organization Focused on transforming
More informationTara Leigh Taylor, MD, FCCP Intensivist, Wyoming Medical Center
Tara Leigh Taylor, MD, FCCP Intensivist, Wyoming Medical Center Objectives Define the magnitude of the problem Define diagnostic criteria of insomnia Understand the risk factors and consequences of insomnia
More informationKEYWORDS: musculoskeletal manipulations, osteopathic medicine, Counterstrain, restless legs syndrome, Randomised controlled trial
Title: Counterstrain manipulation in the treatment of Restless Legs Syndrome: a pilot single-blind randomised controlled trial; the CARL Trial. Peters, T 1, MacDonald, R* 1, Leach, CMJ 2 1 London College
More informationTreatment and Interventions for Opioid Addictions: Challenges From the Medical Director s Perspective
Treatment and Interventions for Opioid Addictions: Challenges From the Medical Director s Perspective Dale K. Adair, MD Medical Director/Chief Psychiatric Officer OMHSAS 1 Treatment and Interventions for
More informationDementia & Movement Disorders
Dementia & Movement Disorders A/Prof Michael Davis Geriatrician ACT Health & GSAHS ANU Medical School Eastern Dementia Network Aged and Dementia Care Symposium Bateman s Bay, 22 October 2010 Types of Dementia
More informationMedication Guide KLONOPIN (KLON-oh-pin) (clonazepam) Tablets
Medication Guide KLONOPIN (KLON-oh-pin) (clonazepam) Tablets Read this Medication Guide before you start taking KLONOPIN and each time you get a refill. There may be new information. This information does
More informationTreating Depression to Remission in the Primary Care Setting. James M. Slayton, M.D., M.B.A. Medical Director United Behavioral Health
Treating Depression to Remission in the Primary Care Setting James M. Slayton, M.D., M.B.A. Medical Director United Behavioral Health 2007 United Behavioral Health 1 2007 United Behavioral Health Goals
More information